Tag:
Protein Sciences
Latest Headlines
Latest Headlines
Protein Sciences plans for battle with vaccine giants
After winning FDA approval for its influenza vaccine in January, Protein Sciences was faced with a problem: how to wrest market share from competitors. The task is complicated by the fact that, as yet, there is little evidence to show it is more effective than rivals.
Universal flu vaccine still 5 to 10 years away
Though the United States has made significant progress in the realm of flu vaccines, the country will likely need to wait 5 to 10 years for a universal shot, top federal health officials said.
Heightened flu season turns focus on vaccine advancements
A heightened flu season and a spate of newly approved influenza vaccines have experts wondering what else they can do to mitigate or prevent the seasonal illness. Next up: A universal flu vaccine administered every 5 to 10 years to fight multiple virus strains and eradicate the need for annual shots.
FDA green-lights a flu vaccine made with new technology
Five years after little Protein Sciences first went to the FDA in search of an approval of its innovative flu vaccine, regulators have finally agreed to hit the green light to permit the biotech to start marketing the jab.
Protein Sciences nabs Flublok approval
A little more than a month after taking over vacated manufacturing space in New York from Pfizer, Protein Sciences won regulatory approval from the FDA for a new type of flu vaccine.
Protein Sciences expands flu vaccine operations to Pfizer site
Protein Sciences will lease two buildings at Pfizer's Pearl River, NY, site to create a production line for its recombinant influenza vaccine Flublok.
Protein Sciences takes over fully equipped Wyeth vaccine plant
One way to start up a vaccine manufacturing operation is to simply take over a mothballed plant left idle by one of Big Pharma's merger shakeouts. That is exactly what Protein Sciences is doing in New York.
Protein Sciences to inhabit Pfizer facilities to make next-gen flu vaccine
The lease gives Meriden, CT-based Protein Sciences access to 83,000 square feet of space at Pfizer's 550-acre Pearl River campus, which has been subject to cutbacks within the past couple of years.
Fungi, caterpillars, plants, bacteria: New frontiers in vaccine production
CHANTILLY, VA - A popular topic at the World Vaccines Congress was cell-based alternatives to egg-based technologies, which was called the next frontier by Dr. Richard Schwartz of NIAID. In recent
Pharma turns to small developers for vax tech
Paul Bogorad at Putnam Associates is bullish about the vaccine business. Reviewing the now familiar story line about Big Pharma's embrace of vaccines after years of neglect, Mass High Tech relates
